Tumor-initiating cells of various tumor types exhibit differential angiogenic properties and react differently to antiangiogenic drugs

Stem Cells

Volumn 30, Issue 9, 2012, Pages 1831-1841

  Benayoun, Liat ^a   Gingis Velitski, Svetlana ^a   Voloshin, Tali ^a   Segal, Ehud ^b   Segev, Rotem ^a   Munster, Michal ^a   Bril, Rotem ^a   Satchi Fainaro, Ronit ^b   Scherer, Stefan J ^c   Shaked, Yuval ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Angiogenesis; Bone marrow derived cells; Cancer stem cells; Chemotherapy

Indexed keywords

ALDEHYDE DEHYDROGENASE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CELL SURFACE MARKER; GEMCITABINE; PACLITAXEL; PROTEIN P21; VASCULOTROPIN ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER STEM CELL; CELL FRACTIONATION; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN MCF 7; CELL VIABILITY; COLON CARCINOMA; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; FLOW CYTOMETRY; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; PANCREAS CANCER; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR CELL LINE; TUMOR CLASSIFICATION; TUMOR INITIATING CELL; TUMOR VOLUME;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL LINE, TUMOR; CELL SURVIVAL; DISEASE MODELS, ANIMAL; HT29 CELLS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; IMMUNOBLOTTING; MCF-7 CELLS; MICE; MICE, NUDE; NEOPLASMS; NEOPLASTIC STEM CELLS; NEOVASCULARIZATION, PATHOLOGIC; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 84865318376     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.1170     Document Type: Article

References (45)

1. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
2. Miller K,WangM, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl JMed 2007;357:2666-2676.
3. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-2550.
4. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378-90.
5. Motzer RJ, Michaelson MD, Redman BG et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:16-24.
6. Ferrara N, Hillan KJ, Gerber HP et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3:391-400.
7. Allegra CJ, Yothers G, O'Connell MJ et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: Results of NSABP protocol C-08. J Clin Oncol 2011;29:11-16.
8. Grunewald M, Avraham I, Dor Y et al. VEGF-induced adult neovascularization: Recruitment, retention, and role of accessory cells. Cell 2006;124:175-189.
9. Jin DK, Shido K, Kopp HG et al. Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes. Nat Med 2006;12:557-567.
10. Shojaei F, Wu X, Malik AK et al. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b(+)Gr1(+) myeloid cells. Nat Biotechnol 2007;25:911-920.
11. Reya T, Morrison SJ, Clarke MF et al. Stem cells, cancer, and cancer stem cells. Nature 2001;414:105-111.
12. Pardal R, Clarke MF, Morrison SJ. Applying the principles of stemcell biology to cancer. Nat Rev Cancer 2003;3:895-902.
13. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: Accumulating evidence and unresolved questions. Nat Rev Cancer 2008;8:755-768.
14. Dontu G, Abdallah WM, Foley JM et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 2003;17:1253-1270.
15. Woodward WA, Chen MS, Behbod F et al. On mammary stem cells. J Cell Sci 2005;118(Pt 16):3585-3594.
16. Dylla SJ, Beviglia L, Park IK et al. Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. PLoS One 2008;3:e2428.
17. Folkins C, Man S, Xu P et al. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res 2007;67:3560-3564.
18. Ginestier C, Hur MH, Charafe-Jauffret E et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007;1:555-567.
19. Ponti D, Costa A, Zaffaroni N et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 2005;65:5506-5511.
20. Bao S, Wu Q, Sathornsumetee S et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 2006;66:7843-7848.
21. Calabrese C, Poppleton H, Kocak M et al. A perivascular niche for brain tumor stem cells. Cancer Cell 2007;11:69-82.
22. Ilan N, Mahooti S, Madri JA. Distinct signal transduction pathways are utilized during the tube formation and survival phases of in vitro angiogenesis. J Cell Sci 1998;111(Pt 24):3621-3631.
23. Gingis-Velitski S, Zetser A, Flugelman MY et al. Heparanase induces endothelial cell migration via protein kinase B/Akt activation. J Biol Chem 2004;279:23536-23541.
24. Adini A, Fainaru O, Udagawa T et al. Matrigel cytometry: A novel method for quantifying angiogenesis in vivo. J Immunol Methods 2009;342:78-81.
25. Gingis-Velitski S, Loven D, Benayoun L et al. Host response to short-term, single-agent chemotherapy induces matrix metalloproteinase-9 expression and accelerates metastasis in mice. Cancer Res 2011;71:6986-6996.
26. Shaked Y, Henke E, Roodhart JMet al. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: Implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 2008;14:263-273.
27. Voloshin T, Gingis-Velitski S, Bril R et al. G-CSF supplementation with chemotherapy can promote revascularization and subsequent tumor regrowth: Prevention by a CXCR4 antagonist. Blood 2011;118:3426-3435.
28. Zhou ZH, Ping YF, Yu SC et al. A novel approach to the identification and enrichment of cancer stem cells from a cultured human glioma cell line. Cancer Lett 2009;281:92-99.
29. Phillips TM, McBride WH, Pajonk F. The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst 2006;98:1777-1785.
30. Viale A, De Franco F, Orleth A et al. Cell-cycle restriction limits DNA damage and maintains self-renewal of leukaemia stem cells. Nature 2009;457:51-56.
31. Huang EH, Hynes MJ, Zhang T et al. Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res 2009;69:3382-3389.
32. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005;5:275-284.
33. Zhou BB, Zhang H, Damelin M et al. Tumour-initiating cells: Challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov 2009;8:806-823.
34. Folkins C, Shaked Y, Man S et al. Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1. Cancer Res 2009;69:7243-7251.
35. Liang WC, Wu X, Peale FV et al. Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J Biol Chem 2006;281:951-961.
36. Beck B, Driessens G, Goossens S et al. A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumours. Nature 2011;478:399-403.
37. Yu SC, Ping YF, Yi L et al. Isolation and characterization of cancer stem cells from a human glioblastoma cell line U87. Cancer Lett 2008;265:124-134.
38. Bertolini G, Roz L, Perego P et al. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci USA 2009;106:16281-16286.
39. Cariati M, Naderi A, Brown JP et al. Alpha-6 integrin is necessary for the tumourigenicity of a stem cell-like subpopulation within the MCF7 breast cancer cell line. Int J Cancer 2008;122:298-304.
40. Gou S, Liu T, Wang C et al. Establishment of clonal colony-forming assay for propagation of pancreatic cancer cells with stem cell properties. Pancreas 2007;34:429-435.
41. Charafe-Jauffret E,Monville F, Ginestier C et al. Cancer stem cells in breast: Current opinion and future challenges. Pathobiology 2008;75:75-84.
42. Kerbel RS. Antiangiogenic therapy: A universal chemosensitization strategy for cancer? Science 2006;312:1171-1175.
43. Wang R, Chadalavada K, Wilshire J et al. Glioblastoma stem-like cells give rise to tumour endothelium. Nature 2010;468:829-833.
44. Ebos JM, Lee CR, Christensen JG et al.Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci USA 2007;104:17069-17074.
45. Arbab AS. Activation of alternative pathways of angiogenesis and involvement of stem cells following anti-angiogenesis treatment in glioma. Histol Histopathol 2012;27:549-557.